Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): A phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Onkologie

Volumn 33, Issue 3, 2010, Pages 89-93

  Trarbach, Tanja ^a   Reinacher Schick, Anke ^b   Hegewisch Becker, Susanne ^c   Vanhoefer, Udo ^d   Frieling, Thomas ^e   Lehnert, Lasse ^f   Schmiegel, Wolff ^b   Graeven, Ullrich ^g  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Private Practice   (Germany)

^d Marienkrankenhaus GmbH   (Germany)

^e HELIOS Clinic Krefeld   (Germany)

^f Astra Zeneca GmbH   (Germany)

^g KLINIKEN MARIA HILF GMBH   (Germany)

Author keywords

Capecitabine; Colorectal cancer; Gefitinib; Phase I study

Indexed keywords

CAPECITABINE; GEFITINIB; IRINOTECAN; OXALIPLATIN;

ACNE; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRY SKIN; FEMALE; HAND FOOT SYNDROME; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; RASH; STOMATITIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; QUINAZOLINES; TREATMENT OUTCOME;

EID: 77949393635     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000277635     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics 2007. CA Cancer J Clin 2007;57:43-66.
2. No authors listed: Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998;16:3537-3541.
3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combination in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
4. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
5. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P, Schilsky RL: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-575.
6. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R: Comparison of oral capecitabine v intravenous 5-fluorouracil plus leucovorin (Mayo clinic regimen) as first-line treatment in 605 patients with metastatic colorectal cancer - results of a randomised phase III study. J Clin Oncol 2001;19:2282-2292.
7. Saif MW: Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer 2005;5:89-100.
8. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115.
9. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
10. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
11. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
12. Rothenberg MI, LaFleur B, Levy DE, Washinton MK, Morgan-Meadows SL, Ramanathan RK, Berlin JD, Benson III AB, Coffey RJ: Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005;23:9265-9274.
13. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth facto receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-2063.
14. Magné N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, Tiffon C, Renée N, Marchetti S, Etienne MC, Milano G: ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 2003;9:4735-4742.
15. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, Johnston P: Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 2005;11:7480-7489.
16. Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, Scartozzi M, Crocicchio F, Mari E, Ardizzoni A: A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR over-expression, amplification and NF-kB activation. Br J Cancer 2008;98:71-76.
17. Gelibter AJ, Gamucci T, Pollera CF, Di Costanzo F, Nuzzo C, Gabriele A, Signorelli C, Gasperoni S, Ferraresi V, Giannarelli D, Cognetti F, Zeuli M: A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. Curr Med Res Opin 2007;23:2117-2123.
18. Zampino MG, Magni E, Massacesi C, Zaniboni A, Martignetti A, Zorzino L, Lorizzo K, Santoro L, Boselli S, de Braud F: First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer 2007;110:752-758.
19. Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS: Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2007;60:661-670.
20. Rosenberg AH, Loehrer PJ, Needle MN, Waksal H, Hollywood E, Ramos L, Saltz LB: Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that express the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002;21:536a.
21. Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH: Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006;17:450-456.
22. Raoul JL, Van Laethem JL, Peeters M, Brezault C, Husseini F, Cals L, Nippgen J, Loos AH, Rougier P: Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 2009;9:112.
23. Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulie P, Casado E, Verslype C, Valera JS, Tortora G, Ciardello F, Kisker O, de Gramont A: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007;25:5225-5232.
24. Arnold D, Höhler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, Wöll E, Herrmann T, Zubel A, Schmoll HJ: Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol 2008;19:1442-1449.
25. Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI: Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 2005;23:5613-5619.
26. Arnold D, Constantin C, Seufferlein T, Gahlemann g, Schmoll HJ, Kretzschmar A: Phase I study of gefitinib in combination with capecitabine and irinotecan for 2nd and/or 3rd line treatment in patients with metastatic colorectal cancer. ASCO Ann Meet Proc, J Clin Oncol 2005;23:abstr 3691.
27. Hofheinz RD, Kubicka S, Wollert J, Arnold D, Hochhaus A: Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin-refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Okologie (AIO). Onkologie 2006;29:563-567.
28. Chau J, Cunningham D, Hickish T, Massey A, Higgins L, Osborne R, Botwood N, Swaisland A: Gefitinib and irinotecan in patients with fluoropyrimidine- refractory, irinotecan-naïve advanced colorectal cancer: a phase I-II study. Ann Oncol 2007;28:730-737.
29. Jimeno A, Gravalos C, Escudero P, Sevilla I, Vega-Villegas ME, Alonso V, Juez I, Garcia-Carbonero R, Bovio H, Colomer R, Cortes-Funes H: Phase I/II study of gefitinib and capecitabine in patients colorectal cancer. Clin Transl Oncol 2008;10:52-57.
30. Hartmann JT, Pintoffl JP, Kröning H, Bokemeyer C, Holtmann M, Höhler T: Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Onkologie 2008;31:237-241.
31. Razis E, Karina M, Karanastassi S, Fountzilas G: Three case reports of hand-foot syndrome with gefitinib. Cancer Invest 2006;24:514-516.